Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Roberts

Showing results (171-180 of 186) with videos related to

Pageof 19
Sort By:
The Journal of Infectious Diseases|October 23, 2014
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individualsSusanne H Hodgson, Katie J Ewer, Carly M Bliss, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 26, 2016
Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and InfantsMuhammed O Afolabi, Alfred B Tiono, Uche J Adetifa, et al.
The Journal of Infectious Diseases|June 17, 2016
Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
The Lancet. Infectious Diseases|December 13, 2024
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in childrenHamtandi M Natama, Jo Salkeld, Athanase Somé, et al.
NPJ Vaccines|October 17, 2018
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 4, 2017
Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and InfantsCarly M Bliss, Abdoulie Drammeh, Georgina Bowyer, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapyRachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
Plos One|March 26, 2013
Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsCaroline Ogwang, Muhammed Afolabi, Domtila Kimani, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 17, 2014
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populationsDomtila Kimani, Ya Jankey Jagne, Momodou Cox, et al.
Nature Medicine|January 6, 2026
Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trialMelissa C Kapulu, Francesca Orenge, Domtila Kimani, et al.
Pageof 19

Showing results (171-180 of 186) with videos related to

Sort By:
Pageof 19
The Journal of Infectious Diseases|October 23, 2014
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individualsSusanne H Hodgson, Katie J Ewer, Carly M Bliss, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 26, 2016
Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and InfantsMuhammed O Afolabi, Alfred B Tiono, Uche J Adetifa, et al.
The Journal of Infectious Diseases|June 17, 2016
Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
The Lancet. Infectious Diseases|December 13, 2024
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in childrenHamtandi M Natama, Jo Salkeld, Athanase Somé, et al.
NPJ Vaccines|October 17, 2018
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 4, 2017
Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and InfantsCarly M Bliss, Abdoulie Drammeh, Georgina Bowyer, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapyRachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
Plos One|March 26, 2013
Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsCaroline Ogwang, Muhammed Afolabi, Domtila Kimani, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 17, 2014
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populationsDomtila Kimani, Ya Jankey Jagne, Momodou Cox, et al.
Nature Medicine|January 6, 2026
Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trialMelissa C Kapulu, Francesca Orenge, Domtila Kimani, et al.
Pageof 19